TY - JOUR T1 - The association of age-related and off-target retention with longitudinal quantification of [<sup>18</sup>F]MK6240 tau-PET in target regions JF - medRxiv DO - 10.1101/2022.05.24.22275386 SP - 2022.05.24.22275386 AU - Cécile Tissot AU - Stijn Servaes AU - Firoza Lussier AU - João Pedro Ferrari Souza AU - Joseph Therriault AU - Pâmela Cristina Lukasewicz Ferreira AU - Gleb Bezgin AU - Bruna Bellaver AU - Douglas Teixeira Leffa AU - Sulantha S. Mathotaarachchi AU - Jenna Stevenson AU - Nesrine Rahmouni AU - Min Su Kang AU - Vanessa Pallen AU - Nina Margherita-Poltronetti AU - Yi-Ting Wang AU - Jaime Fernandez-Arias AU - Andrea L. Benedet AU - Eduardo R. Zimmer AU - Jean-Paul Soucy AU - Dana L. Tudorascu AU - Annie D. Cohen AU - Madeleine Sharp AU - Serge Gauthier AU - Gassan Massarweh AU - Brian Lopresti AU - William E. Klunk AU - Suzanne L. Baker AU - Victor L. Villemagne AU - Pedro Rosa-Neto AU - Tharick A. Pascoal Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/28/2022.05.24.22275386.abstract N2 - Introduction [18F]MK6240 is a tau-PET tracer that quantifies brain tau neurofibrillary tangles (NFT) load in Alzheimer’s disease (AD). The aims of our study are to test the stability of common reference regions estimates in the cerebellum over time and across diagnoses and evaluate the effects of age-related and off-target retention in the longitudinal quantification of [18F]MK6240 in target regions.Methods We assessed reference, target, age-related and off-target regions in 125 individuals across the aging and AD spectrum with longitudinal [18F]MK6240 standardized uptake values (SUV) and ratios (SUVR) (2.25± 0.4 years of follow-up duration). We obtained SUVR values from meninges, a region exhibiting frequent off-target retention of [18F]MK6240, as well as compared tracer uptake between cognitively unimpaired young (CUY, mean age: 23.41± 3.3 years) and cognitively unimpaired older adults (CU, amyloid-β and tau negative, mean age: 58.50± 9.0 years) to identify possible, non-visually apparent, age-related signal. Two-tailed t-test and Pearson correlations tested the difference between groups and associations between changes in region uptake, respectively.Results Inferior cerebellar grey (CG) and full CG presented stable SUV cross-sectionally and over time, across diagnosis and Aβ status. [18F]MK6240 uptake was significantly different between CU young and adults mostly in putamen/pallidum (affecting ∼75% of the region) but also in Braak II region (affecting ∼35%), comprised of the entorhinal cortex and hippocampus. Changes in meningeal and putamen/pallidum SUVRs were not significantly different from zero, nor varied across diagnostic groups. We did not observe significant correlations between longitudinal changes in age-related or meningeal off-target retention and changes in target regions, whereas changes in all target regions were highly correlated.Conclusion Inferior and full CG were similar across diagnostic groups cross-sectionally and stable over time, and thus were deemed suitable reference regions for quantification. Despite this not being visually perceptible, [18F]MK6240 has age-related retention in subcortical regions, in much lower magnitude but topographically co-localized with the most significant off-target signal of the first-generation tau tracers. The lack of correlation between changes in age-related/meningeal and target retention suggests little influence of possible off-target signals on longitudinal tracer quantification. On the other hand, the age-related tracer retention in Braak II needs to be further investigated. Future post-mortem studies should elucidate the source of the newly reported age-related [18F]MK6240 signal, and in vivo studies should further explore its impact on tracer quantification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Weston Brain Institute, Canadian Institute of Health Research, Fonds de Recherche Sante-Quebec and Heatlhy Brains for Healthy lives.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data was acquired at the McGill Center for Studies in Aging, and the project was approved by the Research Ethics Board of the Douglas Mental Health Institute. Written consent has been obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -